Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
betaSENSE
About
  2. Companies
  3. betaSENSE
  4. Products
  5. betaSENSE - Infrared Spectroscopy ...

betaSENSE - Infrared Spectroscopy Platform Technology for Early Detection of Neurodegenerative Diseases

SHARE
betaSENSE has developed a cutting-edge platform technology leveraging the principles of infrared spectroscopy to advance diagnostics in neurodegenerative disorders. The technology, known as betaSENSE, utilizes differential spectroscopy to detect minute changes between states of a sample by subtracting absorption spectra, thereby highlighting protein signals such as amyloid-beta and alpha-synuclein on functionalized biochips. This approach allows differentiation of protein secondary structures by their unique infrared absorption characteristics, aiding in early detection of diseases like Alzheimer's and Parkinson's. The technology facilitates early intervention by identifying amyloid-beta deposits linked to Alzheimer's well before symptomatic onset, using specific antibodies to study extracted proteins. Similarly, in Parkinson's disease, the platform detects misfolded alpha-synuclein proteins that form Lewy bodies. The platform supports the pharmaceutical research in drug discovery and clinical studies, offering reliable risk stratification of participants. Being rigorously tested, this platform represents a significant step in precision medicine, aimed at altering the progression of neurodegenerative diseases.
Most popular related searches
neurodegenerative disease
amyloid beta
pharmaceutical research
clinical research study
Alzheimer disease
body fluid
drug discovery
neurodegeneration
drug research
clinical study

The betaSENSE method, based on a new platform technology, combines the findings of years of cutting-edge research in the field of protein science. In clinical application, it offers researchers new perspectives and facilitates the development of drugs.

Pharmaceutical research  (drug discovery)

To discover new active ingredients and develop drugs, pharmaceutical research requires suitable methods and technologies. With its innovative platform technology, betaSENSE offers researchers a precise method for measuring pharmaceutical mechanisms of action.

Identification of people at risk for studies

The betaSENSE method allows for reliable verification of entry criteria for participants in clinical trials. The differentiated risk assessment provides valuable information for potentially necessary changes to the participant setup.

Prerequisite for next steps created

betaSENSE offers analytics under GCLP conditions for pharmaceutical companies and clinical research studies.

Infrared spectroscopy is an analytical method for detecting small changes between two states of a sample. Two absorption spectra are subtracted from each other to obtain a difference signal. In the betaSENSE method, the signal from the previously functionalized biochip is subtracted from the sample signal. This reveals the additional protein signal (amyloid beta or alpha-synuclein) on the surface. Different secondary structures absorb differently in the infrared range, making identification possible. 

Our procedure using Alzheimer’s as an example.

What begins with a body fluid test, thanks to the betaSENSE procedure, leads to the possibility of detecting various neurodegenerative diseases before symptoms appear. The procedure is explained step by step using Alzheimer's as an example.

Our procedure, using Parkinson's as an example.
What begins with a body fluid test, thanks to the betaSENSE procedure, leads to the possibility of detecting various neurodegenerative diseases before symptoms appear. The procedure is explained step by step using Parkinson's as an example.

The basis of the betaSENSE technology: The misfolding of amyloid-beta (Aß) in Alzheimer's disease and alpha-synuclein (aSyn) in Parkinson's disease as a biomarker.

  • Reliable prognosis for early-stage risk in Alzheimer's disease
  • Reliable differentiation of different forms of disease
  • More than 10 years ahead in prevention and therapy
  • A blood sample is sufficient